DYADIC INTERNATIONAL INC. - COMMON STOCK

Dyadic to Attend Industry Events in April

27 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

26 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

21 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

14 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 Mar 2024 09:57:14 By Nasdaq GlobeNewswire

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

11 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend Industry Events in March

01 Mar 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

28 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

23 Feb 2024 02:00:00 By Nasdaq GlobeNewswire

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

21 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

13 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

06 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

01 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

02 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Dyadic Attends Investor Events in December

30 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

29 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Dyadic’s C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

20 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

08 Nov 2023 16:00:00 By Nasdaq GlobeNewswire

Dyadic to Present at Industry Events in November

30 Oct 2023 08:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

25 Oct 2023 16:30:00 By Nasdaq GlobeNewswire